DE69527975T2 - Humanisierte antikörper gegen cd38 - Google Patents

Humanisierte antikörper gegen cd38

Info

Publication number
DE69527975T2
DE69527975T2 DE69527975T DE69527975T DE69527975T2 DE 69527975 T2 DE69527975 T2 DE 69527975T2 DE 69527975 T DE69527975 T DE 69527975T DE 69527975 T DE69527975 T DE 69527975T DE 69527975 T2 DE69527975 T2 DE 69527975T2
Authority
DE
Germany
Prior art keywords
antibody
sequence
framework region
cdrs
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69527975T
Other languages
English (en)
Other versions
DE69527975D1 (de
Inventor
Jonathan Henry Ellis
Alan Peter Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69527975D1 publication Critical patent/DE69527975D1/de
Publication of DE69527975T2 publication Critical patent/DE69527975T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69527975T 1994-12-02 1995-11-28 Humanisierte antikörper gegen cd38 Expired - Lifetime DE69527975T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9424449A GB9424449D0 (en) 1994-12-02 1994-12-02 Antibodies
PCT/GB1995/002777 WO1996016990A1 (en) 1994-12-02 1995-11-28 Humanized antibodies to cd38

Publications (2)

Publication Number Publication Date
DE69527975D1 DE69527975D1 (de) 2002-10-02
DE69527975T2 true DE69527975T2 (de) 2003-03-27

Family

ID=10765384

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527975T Expired - Lifetime DE69527975T2 (de) 1994-12-02 1995-11-28 Humanisierte antikörper gegen cd38

Country Status (9)

Country Link
US (1) US20050158305A1 (de)
EP (1) EP0794966B1 (de)
JP (1) JPH10509876A (de)
AT (1) ATE222928T1 (de)
AU (1) AU3933695A (de)
DE (1) DE69527975T2 (de)
ES (1) ES2181795T3 (de)
GB (1) GB9424449D0 (de)
WO (1) WO1996016990A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741444B2 (en) 2002-07-04 2010-06-22 Patrys Limited Neoplasm specific antibodies and uses thereof
US8124080B2 (en) 2003-11-14 2012-02-28 Patrys Limited Human monoclonal antibody having fat-reducing effect
US8562995B2 (en) 2003-03-14 2013-10-22 Patrys Limited Neoplasm specific antibodies and uses thereof
US8741296B2 (en) 2003-11-14 2014-06-03 Patrys Limited Adenocarcinoma specific antibody SAM-6, and uses thereof

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69920897T2 (de) 1998-04-28 2005-10-13 Smithkline Beecham Corp. Monoklonale antikörper mit verringerter immunisierungsfähigkeit
EP1174440A1 (de) * 2000-07-19 2002-01-23 U-BISys B.V. Ein selektiv exprimiertes Epitop auf das menschliches CD38 Molekül detektiert von einem "phage display library"-derivierten menschlichen scFv Antikörperfragment
EP2298717B1 (de) 2001-11-30 2015-10-28 Biogen MA Inc. Antikörper gegen chemotaktische Proteine
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
HUE025369T2 (en) * 2004-02-06 2016-02-29 Morphosys Ag Human antibodies against CD38 and their use
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
EP2799451A1 (de) * 2005-05-24 2014-11-05 MorphoSys AG Gewinnung und Profiling von vollständig humanen, von HUCAL-Gold(RTM)-abgeleiteten therapeutischen, für humanes CD38 spezifischen Antikörpern
KR20100084706A (ko) 2005-06-20 2010-07-27 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BRPI0618399B1 (pt) 2005-10-12 2023-10-03 Morphosys Ag Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
JP5328018B2 (ja) * 2006-06-05 2013-10-30 国立大学法人広島大学 抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (de) * 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
US7723485B2 (en) 2007-05-08 2010-05-25 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US20110305693A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Anitigen-binding constructs
WO2010097394A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
EP2401298A1 (de) 2009-02-24 2012-01-04 Glaxo Group Limited Antigenbindende konstrukte
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
CA2758842A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Fgfr1c antibody combinations
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
EP3369744A1 (de) 2010-11-23 2018-09-05 Glaxo Group Limited Antigenbindende proteine zur bindung von oncostatin m (osm)
CA2818621A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
JP6263467B2 (ja) 2011-05-27 2018-01-17 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質
EP2888279A1 (de) 2012-08-22 2015-07-01 Glaxo Group Limited Anti-lrp6-antikörper
GB201216002D0 (en) * 2012-09-07 2012-10-24 Deutsches Rheuma Forschungszentrum Berlin Drfz Compositions adn methods
EP3712177A1 (de) 2013-03-15 2020-09-23 GlaxoSmithKline Intellectual Property Development Limited Anti-lag-3 bindende proteine
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
EA035979B1 (ru) 2014-09-09 2020-09-08 Янссен Байотек, Инк. Варианты комбинированной терапии анти-cd38 антителами
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
CA2986594A1 (en) 2015-05-20 2016-11-24 Tufts Medical Center, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
SI3303373T1 (sl) 2015-05-30 2020-07-31 Molecular Templates, Inc. Deimunizirana ogrodja A podenot Shiga toksina in celice-ciljajoče molekule, ki jih obsegajo
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN108699145A (zh) 2015-09-02 2018-10-23 伊缪泰普有限公司 抗lag-3抗体
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
KR20180067693A (ko) 2015-11-03 2018-06-20 얀센 바이오테크 인코포레이티드 항-cd38 항체의 피하 제제 및 이의 용도
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
KR20200079293A (ko) 2017-10-31 2020-07-02 얀센 바이오테크 인코포레이티드 고위험 다발성 골수종을 치료하는 방법
WO2020264321A1 (en) * 2019-06-26 2020-12-30 The Johns Hopkins University Methods and materials for targeted expansion of immune effector cells
BR112021025476A2 (pt) 2019-06-26 2022-10-11 Glaxosmithkline Ip Dev Ltd Proteínas de ligação à il1rap
MX2021015433A (es) 2019-07-02 2022-06-08 Hutchinson Fred Cancer Res Vectores ad35 recombinantes y mejoras de la terapia génica relacionadas.
KR20230028386A (ko) * 2020-06-17 2023-02-28 와이-맙스 테라퓨틱스 인코포레이티드 인간 질환의 치료를 위한 cd38 항체
WO2022169825A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
JPH07504334A (ja) * 1992-12-10 1995-05-18 セルテック・リミテッド Ａ３３抗原に対するヒト化抗体
WO1994017184A1 (en) * 1993-01-29 1994-08-04 Schering Corporation Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741444B2 (en) 2002-07-04 2010-06-22 Patrys Limited Neoplasm specific antibodies and uses thereof
US8562995B2 (en) 2003-03-14 2013-10-22 Patrys Limited Neoplasm specific antibodies and uses thereof
US8124080B2 (en) 2003-11-14 2012-02-28 Patrys Limited Human monoclonal antibody having fat-reducing effect
US8741296B2 (en) 2003-11-14 2014-06-03 Patrys Limited Adenocarcinoma specific antibody SAM-6, and uses thereof
US9273125B2 (en) 2003-11-14 2016-03-01 Patrys Limited Human monoclonal antibody having fat-reducing effect

Also Published As

Publication number Publication date
EP0794966B1 (de) 2002-08-28
US20050158305A1 (en) 2005-07-21
ATE222928T1 (de) 2002-09-15
WO1996016990A1 (en) 1996-06-06
EP0794966A1 (de) 1997-09-17
ES2181795T3 (es) 2003-03-01
AU3933695A (en) 1996-06-19
JPH10509876A (ja) 1998-09-29
DE69527975D1 (de) 2002-10-02
GB9424449D0 (en) 1995-01-18

Similar Documents

Publication Publication Date Title
DE69527975D1 (de) Humanisierte antikörper gegen cd38
BRPI0413489A (pt) composições polipeptìdicas de ligação a cd20
MXPA05003621A (es) Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
DE69429095T2 (de) Humanisierte antikoerper
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
TR200202254T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
MY154009A (en) Anti-alpha v beta 6 antibodies
DE69535319D1 (de) Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
DE69125485D1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
DK0493446T3 (da) Behandling af autoimmunsygdom.
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
WO2023004036A3 (en) Anti-fsh antibodies for neurodegenerative diseases
HUP0301085A2 (hu) Új peptid és alkalmazása szelektálási eljárásra
UA93478C2 (ru) Выделенное моноклональное антитело человека, kotopoe связывается c cd20, и его применение